Abstract

Cancer being one of the most dreadful disease and inflammation in cancer is one of the emerged Hall marks of cancer. Discovering new drugs with minimal side effects plays vital role in drug development process for the treatment of cancer. As an approach antitumor hybrid of “Benzophenone coupled with diamide analogue “BT009K” or N-(2-{2-[4-(4-bromo-benzoyl)-2-methyl-phenoxy]-acetylamino}-phenyl)-2-[2-methyl-4-(2-methyl-benzoyl)-phenoxy] was screened against different cell lines. Cytotoxic effect was found to be effective against EAC with prolonged effect. The in-vivo antitumor effect was observed in EAC ascites tumour model system with reduced peritoneal neovascularisation. Further histological examination with endothelial marker CD31 confirmed angioregressive effect of BT009K. The results were additionally confirmed in non-tumorigenic model like CAM and rat corneal angiogenesis assay indicating reduced micro vessel density count by BT009K. Further BT009K induces anti-invasive effect in EAC cells in-vitro which could be further developed into therapeutic potential

Key words: Inflammation, angiogenesis, BT009K,MVD